Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transdermal vs Oral Oxybutynin in Pediatric OAB
NCT07081906Completed
- Sponsor
- Kartal Dr. Lütfi Kırdar City Hospital
- Start
- Feb 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of oxybutynin in overactive bladder (OAB) (2 arms), sponsored by Kartal Dr. Lütfi Kırdar City Hospital. Primary endpoint: Dysfunctional Voiding and Incontinence Symptom Score at 3 months. Started Feb 2019; status: completed.
02
Drugs
oxybutynin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT07081906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07081906.